The Evaluation of Red Cell Distribution Width in Chronic Hemodialysis Patients

Table 1

The clinical and demographic characteristics of the patients.

Parameter	Group 1 (𝑛=92)	Group 2 (𝑛=81)	Group 3 (𝑛=74)	Group 4 (𝑛=49)	𝑃
Age (years)	67.6±11.3	63.5±9.2	70.7±14.9	64.9±10.8	>0.05^∗
Gender (female/male) (𝑛)	39/53	37/44	30/44	21/28	>0.05^‡
HD duration (months)	66.1±24.9	62.8±20.3	68.7±31.3	71.2±26.3	>0.05^†
Presence of DM (yes/no) (n)	37/55	29/52	23/51	19/30	𝟎.𝟎𝟐𝟗^‡
Presence of CAD (yes/no) (n)	17/75	16/65	12/62	13/36	𝟎.𝟎𝟒𝟑^‡
Presence of Rtx history (yes/no) (𝑛)	4/88	2/79	3/71	1/48	>0.05^‡
Predialysis systolic BP (mm Hg)	118.9±15.7	115.9±18.1	110.3±14.1	112.7±12.9	>0.05^∗
Predialysis diastolic BP (mm Hg)	74.2±12.3	71.8±13.4	67.5±10.1	69.2±11.6	>0.05^∗
Iron/EPO treatment (present/absent)	0/296	0/81	0/74	0/49	−−−
Anti-P treatment (present/absent) (n)	55/37	38/43	21/53	19/30	𝟎.𝟎𝟏𝟑^‡
Interdialytic weight gain (kg)	1.82±0.52	1.69±0.47	1.95±0.44	1.91±0.54	>0.05^∗
Cardiothoracic index (%)	39.1±7.7	41.2±6.4	38.2±7.6	43.5±5.1	>0.05^∗

Differences assessed by ANOVA* (for parametrical data) or Kruskal-Wallis test^† (for nonparametric data) for numerical variables and by Chi-square test^‡ for categorical variables. Statistically significance: 𝑃<0.05.
HD: hemodialysis, DM: diabetes mellitus, CAD: coronary artery disease, Rtx: renal transplantation, BP: blood pressure, EPO: erythropoietin, and P: phosphate.